Research - With biotech where it is, we're suggesting taking profits on a number of our big winners in the past 6 months. Here are the details on CEMP, BLUE, TRIL, SAGE, MRNS, SGYP, GBIM, QURE, and TKMR.
Read nowInsights - Just a day after Retrophin (RTRX) announced a $100 million financing the U.S. FDA has approved its Cholbam (cholic acid) for pediatric and adult patients with bile … Continue Reading
Read nowInsights - A draft of the 21st Century Cures Act carries serious implications for biopharma. Longer exclusivity, a faster approval process, and even the chance to SELL some exclusivity for certain products.
Read nowInsights - That's what Regeneron (REGN) and Sanofi (SNY) paid for a FDA Priority Review Voucher that will shorten the review time for the PCSK9 inhibitor, alirocumab.
Read nowResearch - This is the first clinical step for “new Tekmira”. Announced last week, Tekmira is merging with OnCore Biopharma to focus on therapeutics for Hepatitis B.
Read now
